Analyzing...
Loading company...
Intelligence analysis not yet available for this company.
“Operates in Pharmaceuticals — Formulations & API.”
₹82 Cr revenue.
COGS 80.6%, employees 1.2%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | - | - |
| ROCE | - | - |
| Net Margin | - | - |
| EBITDA Margin | - | - |
| Debt To Equity | - | - |
| Current Ratio | - | - |
| Rev Growth 3yr | - | - |
| EPS Growth 3yr | - | - |
| Asset Turnover | - | - |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|---|
| Other Income | ₹0.01 Cr 0.0% | ₹0.01 Cr -98.1% | ₹0.52 Cr 0.0% | ₹0.52 Cr -68.3% | ₹2 Cr 0.0% | ₹2 Cr |
| Total Income | ₹82 Cr 0.0% | ₹82 Cr +74.3% | ₹47 Cr 0.0% | ₹47 Cr +5.8% | ₹44 Cr 0.0% | ₹44 Cr |
| COGS | ₹66 Cr 0.0% | ₹66 Cr +70.2% | ₹39 Cr 0.0% | ₹39 Cr +12.1% | ₹35 Cr 0.0% | ₹35 Cr |
| ₹76 Cr 0.0% | ₹76 Cr +75.4% | ₹43 Cr 0.0% | ₹43 Cr +6.2% | ₹41 Cr 0.0% | ₹41 Cr | |
| Profit Before Tax | ₹6 Cr 0.0% | ₹6 Cr +61.5% | ₹4 Cr 0.0% | ₹4 Cr +2.2% | ₹4 Cr 0.0% | ₹4 Cr |
| ₹2 Cr 0.0% | ₹2 Cr +581.7% | ₹0.29 Cr 0.0% | ₹0.29 Cr -68.1% | ₹0.91 Cr 0.0% | ₹0.91 Cr | |
| Net Profit | ₹4 Cr 0.0% | ₹4 Cr +18.5% | ₹4 Cr 0.0% | ₹4 Cr +24.9% | ₹3 Cr 0.0% | ₹3 Cr |
| Other Comprehensive Income | (₹0.00 Cr) 0.0% | (₹0.00 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| EPS | ₹0.63 | ₹0.63 | ₹0.53 | ₹0.53 | ₹0.43 | ₹0.43 |
| Diluted Shares | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Jfl Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. under subscription of the Rights Issue
Jfl Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Jfl Life Sciences Limited has informed the Exchange regarding 'Outcome of Board Meeting held on Wednesday, March 04, 2026 to discuss matters pertaining to Rights Issue'.
Jfl Life Sciences Limited has informed the Exchange that Record date for the purpose of Rights is 10-Mar-2026.
Jfl Life Sciences Limited has informed the Exchange that Board of Directors at its meeting held on March 04, 2026, has decided to issue equity shares on rights basis in the ratio of 1 : 1, i.e 1 Equit...
Jfl Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Jfl Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025
Jfl Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.